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A B S T R A C T
Preadipocyte migration is vital for the development of adipose tissue, which plays a crucial role in lipid
metabolism. ADP-ribosylation factor 6 (ARF6) small GTPase, which regulates membrane trafﬁcking, is
activated by GTP-exchange factors (GEFs) such as cytohesin 2. Cytohesin 2 and ARF6 have previously
been implicated in the regulation of 3T3-L1 preadipocyte migration. We investigated here the molecular
mechanism underlying the cytohesin 2 and ARF6 mediated regulation of preadipocyte migration.
Preadipocyte migration and the activation of ARF6 and ERK1/2 were studied by using a number of
approaches, including pharmacological inhibitors, siRNA and the inhibitory peptides. The siRNA
mediated down regulation of ARF6 and cytohesin 2 expression conﬁrmed the requirement of both for
migration of preadipocytes. Phosphatidylinositol 3-kinase (PI3K) and PI 4,5-bisphosphate (PIP2) have
also found to be essential for the cytohesin 2/ARF6 induced preadipocyte migration. Pharmacological
inhibition of the activation of ARF6, ERK1/2 or dynamin led to signiﬁcant reduction in migration of 3T3-
L1 preadipocytes. Furthermore, our study revealed the activation of ARF6 and ERK1/2 during migration
of preadipocytes. In the migrating preadipocytes, ARF6 activation was inhibited with SecinH3 (cytohesin
inhibitor) and LY294002 (PI3K inhibitor) whereas the ERK1/2 phosphorylation was inhibited with
SecinH3, LY294002, PBP10 (a PIP2 sequester peptide) and PD98059 (MAPKK inhibitor). However,
dynosore (dynamin inhibitor) had inhibited neither ARF6 activation nor ERK1/2 phosphorylation during
preadipocyte migration. These results together suggest that cytohesin 2 activates ARF6 in a PI3K
dependent manner and then the active ARF6 causes phosphorylation of ERK1/2 during preadipocyte
migration.
Crown Copyright  2014 Published by Elsevier Inc. All rights reserved.
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Cell migration is an important and tightly co-ordinated process
for development and maintenance of tissue structures [1]. The
movement of cells is controlled by spatial and temporal changes in
cell membrane shape, which is driven by actin cytoskeleton
[1]. The actin cytoskeleton causes morphological changes (such as
ﬁlopodia, lamellipodia and actin stress ﬁbres formation) at the
plasma membrane, which are regulated by various small GTPases
including ADP-ribosylation factors (ARFs) [1,2]. Preadipocyte
migration is an important stage in the process of adipocyte tissue
formation [3]. Adipocyte tissue formation is initiated with the
proliferation of mesenchymal stem cells (MSCs), which then
differentiate into immature adipocytes [3]. The preadipocytes
migrate to different sites before undergoing further differentiation
to form mature adipocytes, which become spherical in shape and
contain lipids droplets [3]. Chronic over-nutrition of adipose tissue
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that inhibits insulin signalling [4].
ARFs are Ras-related small GTPases, which are about 20 kDa in
size. They cycle between the active GTP bound and inactive GDP
bound conformations [5]. ARFs are regulated through activation by
guanine nucleotide-exchange factors (GEFs) and inactivation by
GTPase-activating proteins (GAPs) [5]. There are six mammalian
ARF proteins (ARFs 1–6), ARF1 and ARF6 are the best characterised
and least related. ARF1 localises to and acts at the Golgi whereas
ARF6 localises to and acts at the cell periphery [6]. ARF6 plays a
pivotal role in cell migration by regulating actin cytoskeletal
remodelling and membrane trafﬁcking at the plasma membrane
[1]. All ARFs, except ARF6, activation is inhibited by Brefeldin A
(BFA), a fungal metabolite, whereas ARF6 activation by cytohesins
is inhibited by a chemical inhibitor SecinH3 [7]. However, QS11,
which is a cell permeable purine derivative, increases the
activation of ARFs by inhibiting the ARF GAP activity [8]. There
are four cytohesin family members in humans (cytohesins 1–4),
each of which contain a pleckstrin homology (PH) domain that
binds to PI 3,4,5-trisphosphate (PIP3). Cytohesins 1–3 have been
shown to translocate from the cytoplasm to the plasma membrane
in a PI3K dependent manner, where they activate ARF6 [9–13].
Cell migration has previously been demonstrated to be
regulated by ARF6 speciﬁc GEFs such as BRAGs (1–3) and exchange
factor for ARF6 (EFA6) [14]. The cytohesin family of ARF GEFs have
also been demonstrated in a variety of cell types to be important
regulators of cell migration [15–17]. Paxillin, a focal adhesion
protein, has been found to interact with and regulate cytohesin
2 activity during the migration of preadipocytes [3]. ERK1/2 and
Rac1 have previously been shown to function downstream of ARF6
in cell migration [16]. The ARF6-dependent activation of ERK1/2
has been shown to be required for epithelial tubule development in
Madin–Darby canine kidney (MDCK) cells and human liver cancer
cell migration stimulated by epidermal growth factor (EGF)
[16,18]. Dynamin has also been linked with cell migration through
its involvement in regulation of the actin cytoskeleton remodel-
ling, focal adhesion disassembly, lamellipodial accumulation and
accumulation of Rac1 at the leading edge of cell during the
migration [19]. In addition, the interaction between dynamin and
cortactin during cell migration has previously been shown to be
potentiated by ERK1/2 phosphorylation [20,21].
In addition to their role in cell migration, both cytohesin 2 and
ARF6 have been implicated in early stages of insulin signalling at
the insulin receptor, where inhibition of signalling led to insulin
resistance in cultured hepatocytes [7,22]. The close relationship of
imbalanced lipid storage and insulin resistance suggests that
cytohesin 2 and ARF6 could play a role in the pathological changes
observed in type 2 diabetes. Consistent with this view, we have
recently shown the involvement ARF6 in endothelin-1 induced
lipolysis in 3T3-L1 adipocytes [23]. In this study, cytohesin 2 and
ARF6 have been found to regulate 3T3-L1 preadipocyte migration
through their downstream signalling effectors ERK1/2 and
dynamin. Furthermore, we have shown that cytohesin 2 activates
ARF6 in a PI3K dependent manner and then the active ARF6 causes
activation/phosphorylation of ERK1/2 during the migration of
preadipocytes.
2. Materials and methods
2.1. Materials
Calf serum (CS) and Dulbecco’s modiﬁed Eagle’s medium
(DMEM) were from Biosera (Uckﬁeld, UK). Dynasore, PD98059 and
SecinH3 were from Abcam (Cambridge, UK). Penetratin, ARF1p-
penetratin and ARF6p-penetratin were synthesised by Thermo
Fisher Scientiﬁc (Cramlington, UK). LY294002 and QS11 were fromR&D Systems Europe Ltd. (Abingdon, UK). Polyphosphoinositide-
Binding Peptide (PBP10) and Cell Comb Scratch Assay were from
Merck Millipore Chemicals Ltd (Beeston, Nottingham, UK).
Brefeldin A (BFA) was from LC Laboratories (MA, USA). OrisTM
Cell Migration Assay 96-well plates were from Platypus Technolo-
gies (Madison, WI, USA). Mouse anti-Arf6 antibody was from Santa
Cruz biotechnology (Santa Cruz, CA). Anti-pERK1/2 and anti-total
ERK1/2 antibodies were from New England Biolabs Ltd. (Hitchin,
UK). siRNA duplexes were synthesised by Eurogentec Ltd. (South-
ampton, UK). All other chemical unless otherwise speciﬁed were
from Sigma–Aldrich (Poole, UK).
2.2. Oris cell migration assay
This assay was carried out according to the manufacturer’s
instructions using Oris cell migration assay kit. Brieﬂy, 0.1 ml of
3T3-L1 preadipocytes (2.5  105 cells/ml) grown in DMEM con-
taining 10% CS, 2 mM glutamine, 100 U/ml penicillin and 0.1 mg/
ml streptomycin (FSM) were seeded in each test well of Oris cell
migration 96-well plates and incubated the plates in a cell culture
incubator for 2 h to permit cell adhesion. Cells seeded in pre-
migration wells in a separate plate were washed three times with
phosphate-buffered saline (PBS), ﬁxed with 4% paraformaldehyde
(PF) for 15 min, washed again with PBS thrice and stored at 4 8C.
After adding test compounds directly to cells seeded wells, the
plate was incubated for a further 24 h to allow cells to migrate. The
wells were then washed with PBS, ﬁxed with 4% PF and washed
again with PBS as for the pre-migration plate. After ﬁxation, both
pre-migration and post-migration wells were stained for nucleus
using DAPI (1 mg/ml; 1:4000 dil.) in PBS for 10 min. The wells were
washed with PBS twice for 5 min. Images of wells were captured
using InCell Analyzer 2000 (GE Healthcare) and cell free area
within detection zone was quantiﬁed using ImageJ software. Cell
migration is presented as percentage closure of cell free zone area,
calculated using the equation ([pre-migration]area Oris[post-
migration]area/[pre-migration]area)  100.
2.3. Cell Comb Scratch Assay
Cell scratches were carried out using Cell Comb Scratch Assay.
3T3-L1 preadipocytes plated in rectangular 1-well plates were
grown in FSM to conﬂuence. After removing the medium, plates
were scratched in one direction with the Cell Comb. Cells were
then washed once with DMEM to remove detached cells, and
incubated in 10 ml of FSM without or with inhibitors for indicated
period. Cells were also incubated for 1–2 h with inhibitors, where
indicated, prior to scratching. Images were captured immediately
after scratching and at indicated time after scratching using a light
microscope equipped with camera (Canon, EOS 600D) and cell
scratch areas were quantiﬁed using ImageJ software. Cell migra-
tion in this assay is presented as percentage closure of cell scratch
area, calculated using the same equation that used for Oris cell
migration assay. Cells were then lysed as described in the
ARF6-GTP pulldown assay and used to assess ARF6 activation
and ERK1/2 phosphorylation.
2.4. ARF6-GTP pulldown assay
This assay was carried out as described previously [24]. The
GST-GGA3 protein binding domain (PBD) fusion protein was
puriﬁed and coupled to glutathione-Sepharose beads (GE Health-
care). Preadipocytes were washed twice in ice-cold PBS and lysed
at 4 8C for 15 min with lysis buffer (500 ml per plate; 25 mM Tris–
HCl [pH 7.2], 150 mM NaCl, 5 mM MgCl2, 1% NP40, 5% glycerol)
containing 1% mammalian protease inhibitor cocktail (Sigma
Aldrich, Poole, UK). The cell lysates were centrifuged at 14,000  g
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lysate was incubated with glutathione-Sepharose beads coupled to
25 mg of puriﬁed GST-GGA3 PBD at 4 8C for 2 h. The beads were
washed three times with wash buffer (50 mM Tris–HCl, pH 7.5,
10 mM MgCl2, 150 mM NaCl, and 1% Triton X-100) and boiled in
50 ml 1 SDS-PAGE loading buffer for 5 min to release the bound
protein into the buffer. The lysates that were not incubated with
the beads were used to assess total ARF6 and ERK1/2 phosphor-
ylation (ERK1/2-p) [23]. ARF6-GTP bound to the beads and total
ARF6, total ERK1/2 and ERK1/2-p in the inputs were determined by
immunoblotting using anti-ARF6 (1:200 dil.), anti-ERK1/2 (1:1000
dil.) and anti-phospho ERK1/2 (1:1000 dil.) antibodies.
2.5. Immunoblotting
Proteins were separated by 12% SDS-PAGE, transferred onto
PVDF membrane and immunoblotted using primary antibodies
and the HRP-conjugated secondary antibodies as described earlier
[25,26].
2.6. siRNA transfection
The speciﬁc target nucleotide sequence of ARF1 siRNA, ARF6
siRNA and cytohesin 2 siRNA was described previously [3,24]. The
siRNA duplex consisting of a unique sequence that does not have
signiﬁcant homology to any mammalian gene sequences was used
as a negative control. Transfection of 3T3-L1 cells with siRNA was
performed when the cells had reached 30–50% conﬂuency. For a
6 cm2 plate, 10 ml Lipofectamine RNAiMAX was diluted in 500 ml
of OPTIMEM. To this, 100 nM siRNA was added. The resulting
mixture was incubated for 15 min at room temperature and then
added to the cells growing in FSM without antibiotics. After 4 h of
incubation, the medium was changed to FSM and left for a further
incubation of 44 h and then used for the cell migration assays and
immunoblotting.
2.7. Inhibition of ARF activation through penetratin-bound inhibitory
peptides
The cell-permeating domain of Drosophila antennapedia
protein (penetratin) and the N-myristoylated ARF1 (ARF1p;
consists of 2–17 aa of ARF1) and ARF6 (ARF6p; consists of 2–13
aa of ARF6) peptides fused to penetratin, to give the property of
membrane permeability, were used in this assay [23,24]. 5 mM
penetratin, 1.5–10 mM ARF1p-penetratin or 1.5–10 mM ARF6p-
penetratin were added to designated wells during the cell
migration assay.
2.8. Statistical analyses
As described in Oris cell migration and Cell Comb Scratch Assays,
preadipocyte migration was quantiﬁed using ImageJ software. Data
presented as percentage closure of cell free zone (Oris cell migration
assay) or scratch (Cell Comb Scratch Assay) was subsequently
analysed using the statistical analysis software programme,
GraphPad Prism. The results are presented as means  standard
deviation (SD). Statistical signiﬁcance was assessed by one-way
ANOVA. A P value <0.05 was considered as statistically signiﬁcant.
3. Results
3.1. ARF6 and cytohesin 2 are involved in the migration of 3T3-L1
preadipocytes
Cytohesin 2, ARF1 and ARF6 have recently been shown to be
involved in 3T3-L1 preadipocyte migration [3]. To conﬁrm the roleof these proteins in preadipocyte migration, we ﬁrst studied the
effect of down regulation of ARF1, ARF6 and cytohesin 2 expres-
sions on preadipocyte migration using previously validated
cytohesin 2, ARF6 and ARF1 siRNAs [3,24]. The speciﬁc down
regulation of target proteins using siRNA was assessed by
immunoblotting (Fig. 1A). ARF1 expression was signiﬁcantly
reduced (approximately 80%) in ARF1 siRNA transfected cells
but not in either ARF6 or cytohesin 2 or negative control siRNA
transfected cells. Similarly ARF6 and cytohesin 2 expression was
considerably depleted (approximately 90%) only in the cells
transfected with ARF6 and cytohesin 2 siRNAs respectively.
Depletion of ARF6 and cytohesin 2 by siRNA treatment signiﬁcant-
ly reduced migration of preadipocytes as assessed by the Oris cell
migration assay (Fig. 1B). As observed previously [3], the reduction
in ARF1 protein expression had the least effect on preadipocyte
migration (76.46%  6.145 vs. 87.75%  6.374 in control, P < 0.05).
ARF6 protein depletion resulted in a greater reduction in preadipo-
cyte migration (57.71%  5.328 vs. control, P < 0.001). The greatest
reduction in preadipocyte migration was observed in cells with down
regulation of cytohesin 2 protein expression (45.31%  6.171 vs.
control, P < 0.001).
3.2. Penetratin coupled ARF6p preferentially inhibits 3T3-L1
preadipocyte migration
To conﬁrm the preferential involvement of ARF6 in the
migration of 3T3-L1 preadipocytes, the inhibitory peptides of
ARF1 and ARF6 (ARF1p and ARF6p) were utilised [24,27,28]. ARF1p
and ARF6p peptides were coupled to the cell-permeating domain
of Drosophila antennapedia protein (penetratin) to make them
membrane permeable. As shown in Fig. 2A, penetratin had no
effect on 3T3-L1 preadipocyte migration whereas ARF1p-pene-
tratin and ARF6p-penetratin inhibited preadipocyte migration.
However, ARF6p-penetratin was more efﬁcient than ARF1p-
penetratin in inhibiting preadiopcyte migration. Both penetratin
coupled ARF1p (Fig. 2B) and ARF6p (Fig. 2C) inhibited migration of
preadipocytes in a dose-dependent manner but greater inhibition
was observed in preadipocytes exposed to ARF6p-penetratin.
ARF1p-penetratin had no effect on preadipocyte migration at
1.25 mM (92.72%  5.480 vs. 96.81%  2.432 in control) but showed
inhibition at higher dose, the maximal affect was at 10 mM dose
(68.23%  3.653 vs. 96.81%  2.432 in untreated control, P < 0.001).
However, ARF6p-penetratin signiﬁcantly inhibited preadipocyte
migration at 1.25 mM (59.38%  3.423 vs. 84.90%  4.6 in control,
P < 0.001). Inhibition of migration increased with increasing dose to
10 mM (41.15%  3.653 vs. control, P < 0.001). These observations,
like those seen in the case for siRNA treatment, highlighted the
preferential involvement of ARF6 in migration of 3T3-L1 preadipo-
cytes. This corresponds with the greater role for ARF6 over ARF1 in
preadipocyte migration described earlier [3].
3.3. ARF6 and ERK1/2 are activated during 3T3-L1 preadipocyte
migration following scratching
A previous study revealed successive activation of ARF6 and
ERK1/2 during migration of hepatoma cells [16]. Since ARF6 is
required for preadipocyte migration, we hypothesised ARF6
activation during preadipocytes migration. As the wells of Oris
cell migration plates we used are of a 96-well format, the Cell Comb
Scratch Assay in 1-well format was employed to scale up the
migration assay to assess biochemical events during preadipocyte
cell migration. We ﬁrst assessed cell migration using the Cell Comb
Scratch Assay. As shown in Fig. 3A, preadipocytes have migrated
68.49% width of the scratch within 4 h. Unlike in the Oris cell
migration assay, the scratch closed completely within 24 h in the
Cell Comb Scratch Assay. This is because the diameter of cell free
Fig. 1. Migration of 3T3-L1 preadipocytes is affected by cytohesin 2 and ARF6 depletion. 3T3-L1 preadipocytes transfected with siRNA for either negative control, ARF1, ARF6
or cytohesin 2 for 48 h were subjected to either immunoblotting (A) or Oris Pro Cell Migration assay (B). (A) The siRNA transfected cells were lysed and 30 mg protein of each
sample was fractionated by SDS-PAGE, immunoblotted with anti-tubulin, anti-ARF1, anti-ARF6 or anti-cytohesin 2 primary antibodies and down regulation of the target
protein was assessed by scanning the blots. (B) Oris cell migration assay wells were seeded with siRNA transfected 3T3-L1 preadipocytes and incubated for 0 h (pre-migration
control) or 24 h to permit cell migration. Then the cells were ﬁxed with 4% paraformaldehyde and stained with DAPI. Migration of 3T3-L1 preadipocytes into cell free zone
(marked by a circle) was determined using the InCell Analyzer 2000 (upper panel), images processed with ImageJ software and cell migration is presented as percentage
closure of the cell free zone (lower panel). The percentage of cell free zone closure done in duplicate is displayed as means  SD of 3 separate experiments. *P < 0.05,
***P < 0.001 compared with no treatment.
Fig. 2. 3T3-L1 preadipocyte migration is inhibited preferentially by penetratin coupled ARF6 inhibitory peptide. The Oris Pro Cell Migration assay wells seeded with 3T3-L1
preadipocytes were incubated independently with 5 mM penetratin, 5 mM ARF1p-pentratin and 5 mM ARF6p-penetratin (A) or varying concentrations (1.25–10 mM) of
ARF1p-penetratin (B) and ARF6p-penetratin (C) for 24 h to permit cell migration. At the end of migration, the cells were ﬁxed with 4% paraformaldehyde and stained with
DAPI. Migration of 3T3-L1 preadipocytes was determined as described in Fig. 1. **P < 0.01, ***P < 0.001 compared with no treatment.
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cell free zones obtained following the cell comb scratch is about
0.2 mm. We next assessed whether ARF6 and ERK1/2 get activated
during cell migration using the Cell Comb Scratch Assay (Fig. 3B/C
& 4). As shown in Fig. 3B, ARF6 was activated within 5 min after
scratching and the ARF6-GTP levels were maintained between
5.4-fold (5 min) and 5.7-fold (240 min) relative to that inunscratched cells (basal levels) during the time course of the
scratch assay. ERK1/2 was also activated (through phosphoryla-
tion) by scratching but the activation occurred later (30 min after
the scratching) when compared to ARF6 activation (Fig. 3 C).
Similar to the ARF6 activation, ERK1/2 activation was maintained
between 6.5-fold (30 min) and 6.1-fold (240 min) relative to that in
unscratched cells. However, we did not observe ARF6 and ERK1/2
Fig. 3. Assessment of time-dependent migration of 3T3-L1 preadipocytes and the activation of ARF6 and ERK1/2 during preadipocytes migration by Cell Comb Scratch Assay.
3T3-L1 preadipocytes were grown to conﬂuent cell monolayers were scratched using the cell comb and incubated for 0–24 h to allow migration of preadipocytes. After that
time, preadipocyte monolayers were viewed under phase contrast microscopy (10), images were captured using a camera (A, upper panel), processed with ImageJ software
and cell migration is presented as percentage closure of the cell scratch area (A, lower panel). The percentage of cell scratch area closure is displayed as means  SD of three
separate experiments. ***P < 0.001 compared with scratch at 0 h.3T3-L1 preadipocytes grown in 1-well plates to conﬂuent cell monolayers were scratched using the cell comb and
incubated in fresh medium for 0–240 min to allow migration of preadipocytes (B & C). The cells in scratched plates at each time point of incubation and a control plate of conﬂuent
preadipocytes were then lysed and incubated the lysates with GST-GGA3 PBD resin to precipitate active ARFs. The protein bound to the resin was analysed by immunoblotting using
an anti-ARF6 antibody to assess the levels of ARF6-GTP. The cell lystes that not incubated with the GST-beads were also immunoblotted with an anti-ARF6 antibody, an anti-ERK
antibody and an anti-ERKphospho speciﬁc antibody for analysing total ARF6, total ERK1/2 and the phosphorylated ERK1/2 (ERK1/2-p) respectively. Densitometric analysis of ARF6-
GTP (B, lower panel) and ERK1/2-p (C, lower panel) is shown as a histogram after normalising them to the levels of total ARF6 (B, upper panel) and ERK1/2 (C, upper panel), respectively,
in the sample. Values are means  SD of three separate experiments. *P < 0.05, **P < 0.01 and ***P < 0.001 compared with scratch at 0 h.
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scratch (24 h after scratching) by preadipocytes migration (Fig. 4).
This result revealed the activation of ARF6 and ERK1/2 during
migration of 3T3-L1 preadipocytes.
3.4. Cytohesin 2 ARF GEF regulate 3T3-L1 preadipocyte migration
The depletion of cytohesin 2 has been shown to prevent the
activation of ARF6, but not ARF1, during preadipocyte migration,
indicating that ARF6 is the substrate for cytohhesin 2 GEF activity
[3]. To determine the role of cytohesin 2 and ARF6 in preadipocyte
migration, we ﬁrst studied the effect of various concentrations
(6.25–50 mM) of SecinH3, a chemical inhibitor for the ARF6
activation by cytohesins, on 3T3-L1 preadipocyte migration over
24 h [7]. SecinH3 inhibited the migration signiﬁcantly at 6.25 mM
(53.65%  3.072 vs. 87.50%  5.929 in control, P < 0.001) and
maximum at 50 mM (38.02%  6.379 vs. control, P < 0.001)
(Fig. 5A). At 50 mM SecinH3, more than 60% of migration of 3T3-L1
preadipocytes was inhibited. This result indicates the involvement of
cytohesin 2 in the migration of 3T3-L1 preadipocytes through ARF6
activation [3].
3.5. Inhibition of ARF6 inactivation increases migration of 3T3-L1
preadipocytes
To further assess the requirement of ARF6 activation in 3T3-
L1 preadipocyte migration, an ARF GAP inhibitor (QS11) wasused to prevent ARF6 inactivation during migration. QS11, a
small purine derivative is a broad spectrum ARF GAP inhibitor
[8]. A dose dependent effect of QS11 (6.25–50 mM) on
preadipocyte migration was tested. As shown in Fig. 5B,
migration of preadipocytes was unaffected by 6.25 mM and
12.5 mM of QS11. However, there was a slight increase in
preadipocyte migration in the presence of 25 mM QS11
(89.58%  3.48 vs. 80.73%  6.379 in control, P < 0.01) and the
migration slightly increased further with 50 mM QS11 treatment
(91.77%  4.097 vs. 80.73%  6.379 in control, P < 0.001). This
result indicates further that the GTP-bound ARF6 is important for
preadipocyte migration.
3.6. PIP2 and PI3K are essential effectors for 3T3-L1 preadipocye
migration
A recent study revealed the necessity of second messenger
PIP3, which produced by PI3K, in the recruitment of cytohesin
2 to the plasma membrane during cell migration and the
membrane recruited cytohesin 2 for activation of ARF6 [29]. We
have also previously shown the PI3K-dependent translocation of
cytohesins 1–3 from the cytosol to the plasma membrane, where
they activate ARF6 [9–13]. To investigate the role of PIP3 in
migration of 3T3-L1 preadipocytes, a chemical inhibitor of PI3K
(LY294002) was used. LY294002 is a reversible and selective
inhibitor of PI3K with the advantage of an increased half-life in
comparison to the other PI3K inhibitors such as wortmannin
Fig. 4. Time-dependent activation of ARF6 and ERK1/2 during 3T3-L1 preadipocyte migration in Cell Comb Scratch Assay. 3T3-L1 preadipocytes grown to conﬂuent cell
monolayers were scratched using the cell comb and incubated for 4 h or 24 h to allow migration of preadipocytes. Cells of plates scratched at each time point and control
plates of conﬂuent preadipocytes were then lysed and subjected to the GST-GGA3 PBD pulldown assay. Total ARF6, ARF6-GTP, total ERK1/2 and ERK1/2-p were analysed by
immunoblotting. The blots are representative of three separate experiments. Densitometric analysis of ARF6-GTP (A, lower panel) and ERK1/2-p (B, lower panel) is shown as a
histogram after normalising them to the levels of total ARF6 and total ERK1/2, respectively, present in the sample. Values are means  SD of three separate experiments.
**P < 0.01 and ***P < 0.001 compared with scratch at 0 min.
Fig. 5. 3T3-L1 preadipocyte migration signals through cytohesin 2, ARF6, ERK1/2 and dynamin. The Oris Pro Cell Migration assay wells seeded with 3T3-L1 preadipocytes were
incubated for 24 h to permit cell migration in the presence of varying concentrations (6.25–50 mM) of the cytohesin inhibitor SecinH3 (A) or ARF GAP inhibitor QS11 (B). After
that, the cells were ﬁxed with 4% paraformaldehyde and stained with DAPI. Migration of 3T3-L1 preadipocytes was determined as described in Fig. 1. **P < 0.01,
***P < 0.001 compared with no treatment.
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messenger PIP3, which subsequently inhibits cytohesin 2 recruit-
ment to the plasma membrane and thereby the activation of
ARF6. ARF6-GTP binds and activates PI 4-phosphate 5-kinase
(PIP5K), leading to a large increase in PIP2 levels at the cell
surface [31]. ARF6-GTP and PIP2 function synergistically to
recruit AP-2 (a component of the clathrin coat complex),
suggesting a role for ARF6 in clathrin mediated internalisation
essential for cell migration [24]. PIP2 sequestering peptide
PBP10, which is a decapeptide derived from the PIP2-binding
region in segment 2 of gelsolin [32], was used to study the role of
PIP2 in preadipocyte migration. As shown in Fig. 6, sequestering
of PIP2 with PBP10 resulted in signiﬁcant inhibition of
preadipocyte migration (53.13%  4.419 vs. 83.05%  3.429 in
control, P < 0.01). Pharmacological inhibition of PI3K by LY294002
also led to signiﬁcant reduction in preadipocyte migration
(40.94%  3.977 vs. control, P < 0.001). These observations high-
light the importance of PIP2 and PI3K in preadipocyte migration.
BFA, an ARF GEF inhibitor that does not prevent the ARF6 activation,
did not affect preadipocyte migration (Fig. 6).3.7. ERK1/2 and dynamin play a role in preadipocytes migration
Hu and colleagues revealed ERK1/2 and Rac1 activation
following ARF6 activation at the plasma membrane during cell
migration [16]. ARF6 dependent activation of ERK1/2 and Rac1 in
epithelial tubule development was also described [18]. Dynamin is
an important GTPase in the process of cell migration, where it
regulates focal adhesion disassembly to allow detachment from
surrounding cells [19]. Dynamin, along with Rac1, also regulates
cell migration through participation in extracellular matrix
degradation and lamellipodial accumulation at the leading edge
of the cell [19].
To determine the role of ERK1/2 and dyanamin in preadipocyte
migration, chemical inhibitors PD98059 and dynasore were used.
PD98059 is a speciﬁc inhibitor for the phosphorylation of ERK1/2
by mitogen-activated protein kinase kinase (MAPKK). Dynasore is
a small molecule inhibitor of dynamin [24]. As shown in Fig. 7A,
inhibition of ERK1/2 phosphorylation with 12.5 mM PD98059
resulted in signiﬁcant inhibition of preadipocyte migration
(62.03%  9.667 vs. 82.34%  5.859 in control, P < 0.01). Migration
Fig. 6. Inhibition of PI3K and depletion of PIP2 reduced 3T3-L1 preadipocyte
migration. The Oris Pro Cell Migration assay wells seeded with 3T3-L1
preadipocytes were treated with PIP2 sequestering peptide PBP10 (10 mM), the
PI3K inhibitor LY294002 (50 mM) or an ARF GEF inhibitor BFA (50 mM) and
incubated for 0 h (pre-migration control) or 24 h to permit cell migration. At the end
of cell migration, the cells were ﬁxed with 4% paraformaldehyde and stained with
DAPI. Migration of 3T3-L1 preadipocytes was determined as described in Fig. 1.
**P < 0.01, ***P < 0.001 compared with no treatment.
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reaching maximal inhibition at 50 mM (46.85%  9.917 vs. control,
P < 0.001). At 50 mM of PD98059, migration of 3T3-L1 preadipocytes
was reduced by almost half that of the control, conﬁrming ERK1/2
involvement in preadipocyte migration. As shown in Fig. 7B,
inhibition of dynamin with dynasore also reduced the migration of
preadipocytes. At 6.25 mM dynasore, migration was signiﬁcantly
inhibited (52.08%  4.27 vs. 85.42%  7.569 in control, P < 0.001) andFig. 7. 3T3-L1 preadipocyte migration signals through ERK1/2 and dynamin. The Oris Pr
24 h to permit cell migration in the presence of varying concentrations (6.25–50 mM) of
cells were ﬁxed with 4% paraformaldehyde and stained with DAPI. Migration of 3T3-L1 pr
with no treatment.the inhibition increased further with increasing concentration to
50 mM (28.23%  9.441 vs. control, P < 0.001). At 50 mM dynasore,
migration of preadipocytes was reduced to less than a third that of the
control. Taken together, these results demonstrate the importance of
ERK1/2 and dynamin in preadipocyte migration. Like in Oris cell
migration assay, SecinH3, PD98059 and dynasore also inhibited
preadipocyte cell migration after scratching, indicating that the
results obtained using the Cell Comb Scratch Assay are comparable
with those of Oris cell migration assay (Fig. 8). When we assessed cell
viability using an alamar blue assay, none of inhibitors at the highest
concentration used in cell migration assay had any effect on
preadipocytes viability (data not shown). This indicates that the
effect of inhibitors used in this study on preadipocytes migration is
speciﬁc.
3.8. ERK1/2 and dynamin are downstream signalling effectors of ARF6
Since inhibition of cytohesin, MAPKK and dynamin lead to
slowdown of 3T3-L1 preadipocyte migration, we further investi-
gated whether these signalling molecules regulate cell migration
by altering the activity of ARF6 and ERK1/2. For this purpose, the
cell migration inhibitors effect, at an optimal concentration, on the
activation of ARF6 and ERK1/2 during preadipocytes migration was
assessed. As shown in Fig. 9A, there was a 5-fold increase in ARF6-
GTP levels during 240 min cell migration. In the presence of
SecinH3 (a cytohesin inhibitor) or LY294002 (a PI3K inhibitor), cell
migration-induced ARF6-GTP was reduced to basal levels, which
correlated with the observed inhibition of preadipocyte migration.
Treatment of preadipocytes with QS11 (an ARF GAP inhibitor) did
slightly increased the ARF6-GTP levels (5.7-fold). However BFA (an
ARF GEF inhibitor that does not prevent ARF6 activation), PD98059
(a MAPKK inhibitor), PBP10 (a PIP2 sequestering peptide) and
dynasore (a dynamin inhibitor) had no effect on the cell migration-
induced activation of ARF6.
As shown in Fig. 9B, there was a 6.4-fold increase in ERK1/2-
phosphorylation/activation during 240 min of cell migration.
SecinH3 inhibited the ERK1/2 activation (2.2-fold vs. 6.4-fold in
control) whereas QS11 increased the ERK1/2 activation to 8.9-fold,
the highest levels of ERK1/2-phosphorylation in the assay. As seen
with the ARF6 activation, BFA and dynasore had no effect on the
cell migration-induced activation of ERK1/2. However, PD98059
inhibited ERK1/2 activation (2.1-fold vs. 6.4-fold in control), which
correlated with the inhibition of migration observed with PD98059
treatment. In the presence of PBP10 or LY294002, ERK1/2o Cell Migration assay wells seeded with 3T3-L1 preadipocytes were incubated for
 the MEKK inhibitor PD98059 (A) or dyanmin inhibitor dynasore (B). After that, the
eadipocytes was determined as described in Fig. 1. **P < 0.01, ***P < 0.001 compared
Fig. 8. Inhibition of cytohesin, ERK1/2 and dynamin activation affects migration of
3T3-L1 preadipocytes in Cell Comb Scratch Assay. 3T3-L1 preadipocytes grown to
conﬂuent cell monolayers in 1-well plates were incubated without or with
inhibitors for 1 h, scratched using the cell comb and incubated again without or
with inhibitors for 4 h to allow migration of preadipocytes. After that time,
preadipocyte monolayers were viewed under phase contrast microscopy (10) and
images were captured using a camera (upper panel), processed with ImageJ software
and cell migration is presented as percentage closure of the cell scratch area (lower
panel). The percentage of cell scratch area closure is displayed as means  SD of
three separate experiments. *P < 0.05, ***P < 0.001 compared with no treatment.
J.C.B. Davies et al. / Biochemical Pharmacology 92 (2014) 651–660658phosphorylation was also reduced to basal levels, correlating with
the observed inhibition of preadipocyte migration. These results
demonstrate that preadipocyte migration signals through the PI3K
and cytohesin ARF GEF mediated activation of ARF6, followed by
that of ERK1/2. This is suggested as PD98059 inhibited preadipo-
cyte migration and ERK1/2 activation during the migration but had
no effect on the activation of ARF6. Previously we have shown thatFig. 9. Inhibition of cytohesin, ERK1/2 and dynamin activation prevents migration of 3T3-
plates to conﬂuent cell monolayers were preincubated without or with inhibitors for 1 h, 
to allow migration of preadipocytes. Cells of plates for each treatment and control plate
pulldown assay. Total ARF6, ARF6-GTP, total ERK1/2 and the phosphorylated ERK1/2 (E
separate experiments. Densitometric analysis of ARF6-GTP (A, lower panel) and ERK 1/2-p
ARF6 (A, upper panel) and ERK1/2 (B, upper panel), respectively, present in the sample. Va
## P < 0.01 compared with scratch/no treatment.ARF6 act upstream of dynamin, by activating it through NM23-H1,
and clathrin, by generating PIP2 through the activation of PIP5K
[24]. Dyanmin has also shown to act down stream of ERK1/2
[20,21,33]. Dynasore and PBP10 had no effect on cell migration-
induced ARF6 activation though they inhibit preadiocyte migra-
tion, indicating that dynamin and PIP2 are also likely to act
downstream of ARF6 in cell migration. Like the ARF6 activation,
cell migration-induced ERK1/2 activation was also unaffected by
dynasore and this suggests that dynamin may act downstream of
ARF6 and ERK1/2. However, ERK1/2 activation during cell
migration was affected by PBP10, suggesting that PIP2 may act
upstream of ERK1/2 phosphorylation.
4. Discussion
The involvement of ARF6 in preadipocyte migration has
recently been described [3]. In this study we have shown that
inhibition of ARF6 activation by SecinH3 results in decreased
migration of 3T3-L1 preadipocytes. In addition, prevention of ARF6
inactivation with an ARF GAP inhibitor (QS11) slightly increases
preadipocyte migration, highlighting further the requirement of
active, GTP-bound, ARF6 for cell migration. Consistent with this,
the siRNA-mediated down regulation of ARF6 and cytohesin
2 proteins expression in preadipocytes results in a substantial
reduction in migration of preadipocytes. ARF6 involvement in 3T3-
L1 preadipocyte migration is also conﬁrmed by using the
membrane-permeable penetratin-coupled ARF6p inhibitory pep-
tide. Taken together these results conﬁrm a previous study [3] that
3T3-L1 preadipocyte migration is regulated through the activation
of ARF6 by cytohesin 2. To complement the cell migration studies,
the activation of ARF6 during cell migration was biochemically
analysed.
The second messenger PIP3, generated by PI3K, recruits
cytohesins, through their PH domains, to the plasma membrane,
where they regulate ARF6 activation [9,34–36]. It is well known
that the activated ARF6 causes several morphological changes at
the plasma membrane, including the formation of cortical actin
[1,12,37]. The requirement of PIP3 for the recruitment ofL1 preadipocytes in Cell Comb Scratch Assay. 3T3-L1 preadipocytes grown in 1-well
scratched using the cell comb and then incubated without and with inhibitors for 4 h
s of conﬂuent preadipocytes were then lysed and subjected to the GST-GGA3 PBD
RK1/2-p) were analysed by immunoblotting. The blots are representative of three
 (B, lower panel) is shown as a histogram after normalising them to the levels of total
lues are means  SD of three separate experiments. ***P < 0.001 compared with basal.
PI3K
Cytohesin
ARF6-GTP
PIP2
ERK1/2-p
Dynamin
Cell migration
LY294002
SecinH3/ARF6-p
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Dynasore
QS11
ARF6-GDP
GAP
Fig. 10. Schematic model representing the ARF6 signalling pathway in migration of
preadipocytes deduced from the present study.
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breast carcinoma SUM159 cells has recently been demonstrated
[29]. In this study, 3T3-L1 preadipocyte migration and ARF6
activation during the migration were shown to be inhibited by the
PI3K inhibitor (LY294002), indicating cytohesin 2 recruitment to
the plasma membrane during cell migration is through PIP3.
In MDCK cells, ARF6 activated during HGF induced tubule
development has been found to signal through ERK1/2 and Rac1
[18]. More recently, ARF6 has been shown to regulate EGF induced
human hepatoma cell migration by signalling through down-
stream activation of ERK1/2 and Rac1 [16]. Rac1 has been shown to
be accumulated with dynamin at the leading edge of the cell during
migration, where it regulates cellular events such as actin
cytoskeleton reorganisation [19]. ERK1/2 phosphorylation has
been shown to stimulate the interaction of dynamin with cortactin,
leading to the actin cytoskeleton remodelling responsible for cell
migration [20,21]. These studies highlight the involvement of
ERK1/2, dynamin and Rac1 in ARF6-mediated actin remodelling
during cell migration.
The involvement of ERK1/2 and dynamin in preadipocyte
migration demonstrated here could possibly be the link between
ERK1/2 and Rac1 in actin cytoskeleton reorganisation at the
plasma membrane in the process [19]. It is also possible that
dynamin might be the stage at which pathways diverge
following the ARF6 activation in cell migration. Dynamin, which
participates in ﬁssion of clathrin-coated vesicles, is activated by
ARF6-GTP through recruiting NM23-HI, a dynamin activator, to
the membrane [24]. Recently, PIP2 and clathrin have been shown
to participate in cell migration. The AP2, which is a part of
clathrin coat complex, interacts with PIP2 at the cell membrane
to initiate cell migration [38]. In this study, PIP2 sequestering
abolished cell migration and ERK1/2 phosphorylation but had no
effect on ARF6 activation, conﬁrming the involvement of PIP2
downstream of ARF6 and upstream of ERK1/2 in cell migration.
This is consistent with a previous study, which suggested PIP2
regulation of ERK1/2 activation during stress induced apoptosis
[33]. Although how PIP2 regulates ERK1/2 activation is unclear, it
is possible that the regulation could involve PI mediated
regulation of Raf, which regulates ERK1/2 activation through
the MAPK pathway [39].
Preadipocyte migration is important for lipid metabolism.
Reduced preadipocyte migration through inhibition of ARF6/
cytohesin2 could have negative consequences on the storage of
cellular lipids. Moreover, adipocyte over-nutrition as a result of
perturbed preadipocyte migration is potentially a key factor in the
initiation of insulin resistance [4]. There remains the possibility of
other GEFs such as BRAGs 1–3 and EFA6 acting on ARF6 during the
process of migration [14]. However, there is no evidence for these
GEFs expression in preadipocyte. In addition to PIs, scaffolding
protein paxillin plays an important role in the recruitment of
cytohesin to the plasma membrane during cell migration
[3]. Scaffolding proteins such as cytohesin 3/Grp1 signalling
partner (GRSP) [34], Grp1-associated scaffold protein (GRASP)/
tamalin [40,41], cytohesin-associated scaffold protein (CASP)/
cytohesin interacting protein (CYTIP) [42,43] and interaction
protein for cytohesin exchange factors (IPCEF)1 [44] are also
involved in cytohesin recruitment. IPCEF1 and GRASP have also
been found to promote signalling of cytohesin 2 and Rac GEF Dock
180 during migration of MDCK cells [45]. It has been suggested that
GRASP and IPCEF1 are responsible for recruitment of cytohesin 2 to
the plasma membrane and thereby promoting ARF6 activation,
which in turn recruits the Dock180/ELMO complex for activation of
Rac1 at the plasma membrane [45]. It is possible that different
combinations of ARF6 GEFs and Rac1 GEFs act together to induce
downstream membrane remodelling events in different cell types.
Therefore, more work regarding this aspect would yield a greaterdetail of the molecular mechanisms underlying preadipocyte
migration. ERK1/2 has shown to be involved in ARF6 induced
activation of Rac1 during EGF induced migration of HepG2 cells
[16]. It is therefore possible that ERK1/2 may also act as an
intermediate between ARF6 and Rac1 in preadipocyte cell
migration.
Cytohesin 2 and ARF6 are also key signalling components of the
insulin receptor, where inhibition of these effectors causes
blocking of insulin signalling and thereby insulin resistance
[7,22]. Therefore, in addition to adipocyte over-nutrition, the
imbalance between insulin signalling and migration of the
preadipocyte could also play a role in insulin resistance. These
pathways and the signalling molecules common to both the
pathways are of particular interest, considering the close associa-
tion between obesity and insulin resistance. For instance in the
case of hyperinsulinaemia, there could be a possible competition
between these two signalling pathways, where increased insulin
signalling through the insulin receptor recruits cytohesins and
ARF6 to the receptor, causing an imbalance favouring redistribu-
tion of the signalling components from the leading edge of the
preadipocyte. Further elucidation of molecular mechanisms could
yield signiﬁcant ﬁndings, leading to therapeutics for insulin
resistance and type 2 diabetes. In summary, we proposed a
pathway for ARF6/cytohesin 2 mediated preadipocyte migration
based on this study (Fig. 10), cytohesin 2 recruits, by binding to
PI3K lipids product (PIP3), to the plasma membrane (PM), where it
activates ARF6. The active ARF6 then increases PIP2 levels, which
leads to phosphorylation of ERK1/2 and subsequent activation of
dynamin, causing actin cytoskeleton remodelling beneath the
plasma membrane that required for cell migration.
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